Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Novartis Pharma Services AG
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A multi-center, randomized, double-blind study to evaluate the efficacy and long-term safety of vildagliptin modified release (MR) as monotherapy in patients with type 2 diabetes
1.To demonstrate the efficacy of vildagliptin MR (25 mg qd or 50 mg qd) as monotherapy in patients with T2DM by testing the hypothesis that the HbA1c reduction with vildagliptin MR is superior to that...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
Phase III, Multicenter Study to Evaluate the Safety, immune response, and effectiveness of Two Doses of aH5N1 vaccine when Administered to Adult and Elderly Subjects With and Without Underlying Diseases
Primary Immunogenicity Objective: To evaluate homologous antibody responses to aH5N1 vaccine 3 weeks after second vaccination (day 43) according to CHMP immunogenicity criteria1 in adult (18 through...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
Dose Finding Study for QAW039 in Asthma
To demonstrate a clinically significant improvement in morning FEV1 in moderate to severe allergic asthmatics inadequately controlled by ICS therapy treated with QAW039 for 12 weeks compared to placeb...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
Assessment of everolimus in addition to calcineurin inhibitors reduction in maintenance renal transplant recipients (ASCERTAIN)
The primary objective is to investigate whether initiation of everolimus together with reduction or discontinuation of CNI in maintenance renal transplant patients with renal impairment will improve r...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A clinical trial to evaluate efficacy and safety of aliskiren and aliskiren/enalapril combination compared to enalapril in patients with heart failure
The primary objectives of this study are to test if aliskiren monotherapy is superior or at least non-inferior to enalapril monotherapy ((in the entire study population) and to test if aliskiren/enala...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A single-blind, double dummy, randomized, multi-dose, two sequence, crossover, study to investigate the Added effects of Renin Inhibitor (aliskiren 300 mg) on Albuminuria in non-diabetic nephropathy patients treated with ramipril 10 mg and Volume intervention (ARIA)
• To investigate the added effects of 300 mg aliskiren on albuminuria in patients with non-diabetic nephropathy treated with ramipril 10 mg and volume intervention.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A 12 month, phase III, randomized, double-masked, multi-center, active-controlled study to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab vs. verteporfin PDT in patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia
To demonstrate the superior efficacy of 0.5 mg ranibizumab driven by stabilization criteria and/or by disease activity re-treatment criteria vs. vPDT (verteporfin Photodynamic Therapy) as assessed by ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A study to test a new drug for treating non-small cell lung cancer
To assess the overall response rate (ORR) in subjects with stage IV BRAF V600E mutant non-small cell lung cancer administered dabrafenib as a single agent (Cohort A) and in combination with trametinib...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
Study of efficacy and safety of secukinumab 2 mL pre-filled syringe (300 mg) in subjects with moderate to severe plaque psoriasis
To demonstrate the efficacy of secukinumab 300 mg when administered as 2 mL pre-filled syringes in subjects with chronic plaque-type psoriasis with respect to both PASI 75 and IGA mod 2011 0 or 1 resp...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A phase III, randomized, double-blind, double-dummy, placebo-controlled, multicenter, 3-period incomplete block, multidose crossover study to determine the effect on lung function of indacaterol (150 and 300 µg o.d.) in patients with moderate to severe COPD using tiotropium (18 µg o.d.) as an active control
To determine if indacaterol (150 µg o.d. and/or 300 µg o.d.) is superior to placebo in terms of 24 h post dose trough FEV1 after 14 days of treatment in each treatment period in patients with COPD.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
20
21
22
23
24
25
26
27
28
29
Suivant